The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study
Open accessAbstract
CONTEXT: Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating this anti-inflammatory effect of statins are not available. OBJECTIVE: To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction. DESIGN, SETTING, AND PARTICIPANTS: Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior history of cardiovascular disease (primary prevention cohort) and open-label study including 1182 patients with known cardiovascular disease (secondary prevention cohort) who provided at least baseline and 12-week blood samples. The study was conducted in US office-based practices from February to December 2000. INTERVENTIONS: Participants in the double-blind primary prevention trial were randomly assigned to receive 40 mg/d of pravastatin (n = 865) or placebo (n = 837) for 24 weeks. Participants in the secondary prevention cohort received 40 mg/d of open-label pravastatin for 24 weeks. MAIN OUTCOME MEASURE: Change in CRP levels from baseline to 24 weeks. RESULTS: In the primary prevention trial, compared with placebo, pravastatin reduced median CRP levels by 16.9% (P<.001) at 24 weeks, reflecting a decrease of 0.02 mg/dL in the pravastatin group while no change in CRP levels was observed in the placebo group. This effect was seen as early as 12 weeks (median reduction in CRP with pravastatin, 14.7%; P<.001) and was present among all prespecified subgroups according to sex, age, smoking status, body mass index, baseline lipid levels, presence of diabetes, and use of aspirin or hormone replacement therapy. No significant association was observed between baseline CRP and baseline LDL-C levels, end-of-study CRP and end-of-study LDL-C levels, or change in CRP and change in LDL-C levels over time. In linear regression analyses, the only significant predictors of change in CRP on a log scale were randomized pravastatin allocation and baseline CRP levels (P<.001 for both). Similar reductions in CRP levels were observed at 12 weeks (-14.3%) and 24 weeks (-13.1%) in the secondary prevention cohort treated with pravastatin (P<.005 for both). CONCLUSIONS: In this prospective trial, pravastatin reduced CRP levels at both 12 and 24 weeks in a largely LDL-C-independent manner. These data provide evidence that statins may have anti-inflammatory effects in addition to lipid-lowering effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Self-citationRidker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Self-citation
Cited by
Items 101–141 of 141
Diamantis, E., Kyriakos, G., Quiles-Sanchez, L. V., Farmaki, P., & Troupis, T. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170426104611 · Cited by 259
Obesity, Type 2 Diabetes, and Cancer Risk
Scully, T., Ettela, A., LeRoith, D., & Gallagher, E. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615375 · Cited by 256
Elkind, M. S. V., Tai, W., Coates, K., Paik, M. C., & Sacco, R. L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2073 · Cited by 255
Arnaud, C., Burger, F., Steffens, S., Veillard, N. R., Nguyen, T. H., Trono, D., & Mach, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000163840.63685.0c · Cited by 247
Brinkworth, G. D., Noakes, M., Keogh, J. B., Luscombe, N. D., Wittert, G. A., & Clifton, P. M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802617 · Cited by 245
Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease
Savarese, G., Gotto, A. M., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.069 · Cited by 219
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Self-citationInflammatory markers and particulate air pollution: characterizing the pathway to disease
Zeka, A., Sullivan, J. R., Vokonas, P. S., Sparrow, D., & Schwartz, J. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl132 · Cited by 205
Bhanpuri, N. H., Hallberg, S. J., Williams, P. T., McKenzie, A. L., Ballard, K. D., Campbell, W. W., McCarter, J. P., Phinney, S. D., & Volek, J. S. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0698-8 · Cited by 190
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182
New insights on oxidative stress in the artery wall
STOCKER, R., & KEANEY, J. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01370.x · Cited by 188
Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease
Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C., & Stefanadis, C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.054 · Cited by 187
Effect of physical activity on serum C-reactive protein
Albert, M. A., Glynn, R. J., & Ridker, P. M. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.046 · Cited by 178
Self-citationWhooley, M. A., Caska, C. M., Hendrickson, B. E., Rourke, M. A., Ho, J., & Ali, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.016 · Cited by 171
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Biomarkers of Cardiovascular Disease as Risk Factors for Age-Related Macular Degeneration
Vine, A. K., Stader, J., Branham, K., Musch, D. C., & Swaroop, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.07.004 · Cited by 160
Inflammation and cortisol response in coronary artery disease
Nijm, J., & Jonasson, L. (2009) · Annals of Medicine · doi:10.1080/07853890802508934 · Cited by 128
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125
N., C., & J., C. (2002) · Diabetologia · doi:10.1007/s00125-002-0975-6 · Cited by 116
Christ, M., Bauersachs, J., Liebetrau, C., Heck, M., Günther, A., & Wehling, M. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2648 · Cited by 107
Paraskevas, K. I., Liapis, C. D., Hamilton, G., & Mikhailidis, D. P. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.03.009 · Cited by 97
Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk
Hammett, C. J. K., Prapavessis, H., Baldi, J. C., Varo, N., Schoenbeck, U., Ameratunga, R., French, J. K., White, H. D., & Stewart, R. A. H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.08.009 · Cited by 95
Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid
Riekse, R. G., Li, G., Petrie, E. C., Leverenz, J. B., Vavrek, D., Vuletic, S., Albers, J. J., Montine, T. J., Lee, V. M.-Y., Lee, M., et al. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10408 · Cited by 90
Novel insights into genetics and clinics of the HNF1A-MODY
Valkovicova, T., Skopkova, M., Stanik, J., & Gasperikova, D. (2019) · Endocrine Regulations · doi:10.2478/enr-2019-0013 · Cited by 84
“On the other hand, statin therapy, which is widely used for decreasing the level of total or LDL-cholesterol in T2D, decreases also the CRP levels (Albert et al. 2001).”
BackgroundLaCroix, A. Z., Gray, S. L., Aragaki, A., Cochrane, B. B., Newman, A. B., Kooperberg, C. L., Black, H., Curb, J. D., Greenland, P., & Woods, N. F. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.4.369 · Cited by 84
Gao, F., Linhartova, L., Johnston, A. M., & Thickett, D. R. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aem406 · Cited by 83
Heilbronn, L. K., & Clifton, P. M. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00187-0 · Cited by 80
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Bielecka-Dabrowa, A., Bytyçi, I., Von Haehling, S., Anker, S., Jozwiak, J., Rysz, J., Hernandez, A. V., Bajraktari, G., Mikhalidis, D. P., & Banach, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1135-z · Cited by 57
Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review
Ding, M., & Qiu, C. (2018) · Current Epidemiology Reports · doi:10.1007/s40471-018-0159-7 · Cited by 57
Oka, S., Matsumoto, T., Kubo, S., Matsushita, T., Sasaki, H., Nishizawa, Y., Matsuzaki, T., Saito, T., Nishida, K., Tabata, Y., et al. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2012.0325 · Cited by 57
Chaudhry, M. Z., Wang, J. H., Blankson, S., & Redmond, H. P. (2008) · Surgical Infections · doi:10.1089/sur.2006.077 · Cited by 56
Statins as modulators of bone formation
Edwards, C. J., & Spector, T. D. (2002) · Arthritis Research & Therapy · doi:10.1186/ar399 · Cited by 53
“Recently, pravastatin has been shown to reduce C-reactive protein in cardiology patients [20].”
BackgroundThe Immunomodulatory Effects of Statins on Macrophages
Sheridan, A., Wheeler-Jones, C. P. D., & Gage, M. C. (2022) · Immuno · doi:10.3390/immuno2020021 · Cited by 48
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?
Blake, G. J., & Ridker, P. M. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00227.2003 · Cited by 47
Self-citationDo Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
Spanakis, E. K., Kourkoumpetis, T. K., Livanis, G., Peleg, A. Y., & Mylonakis, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0447 · Cited by 31
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
New Clinical Markers Predictive of Cardiovascular Disease: The Role of Inflammatory Mediators
Rackley, C. E. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000126083.86717.5b · Cited by 14
“Although the concomitant use of aspirin and statins on CRP levels and CHD events has not been well studied, in the Pravastatin Inflammation/CRP Evaluation (PRINCE) study the reduction in CRP after 24 weeks of pravastatin (40 mg/d) was similar among aspirin users and non–aspirin users.(50)”
ResultTreatment with w-3 fatty acids reduces serum C-reactive protein concentration
Muhammad, K., Morledge, T., Sachar, R., Zeldin, A., Wolski, K., & Bhatt, D. (2011) · Clinical Lipidology · doi:10.2217/clp.11.54 · Cited by 10
Metadata
- Authors
- Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-07-04
- Volume
- 286
- Issue
- 1
- Pages
- 64
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2070396041
- Cited by
- 1,641
- References
- 30
- FWCI
- 112.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.